RxDoctor Payments DataLook up a doctor →

Mugdha Agrawal, MD

Rheumatology · Voorhees, NJNPI 1144595414

Payments from drug & device makers

$51,675in general payments, 2019–2025

Across 374 payments — averaging $138.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$45K
  • AbbVie$1K
  • Amgen$1K
  • Johnson & Johnson$641
  • Pfizer$600
  • Novartis$436
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,73696%
  • Education$2464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,675 in reported general payments places this provider in the 85th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,942,041
Medicare patients
741
Services billed
128,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab14$99,359
Humira(Cf)Adalimumab12$80,048
MethotrexateMethotrexate Sodium182$5,245
Hydroxychloroquine Sulfate81$4,239
Leflunomide54$2,576
Colchicine11$968
Sulfasalazine33$936
Prednisone167$868
Tramadol Hcl73$587
Allopurinol47$576
Gabapentin48$544
Duloxetine Hcl25$474
Sulfasalazine DrSulfasalazine16$462
Pregabalin24$376
Alendronate Sodium50$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$1,395$80,04812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Voorhees

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →